Abstract: The present inventors discovered that an HMGB1 fragment peptide having a particular amino acid sequence exhibits effects of inhibiting finger adhesion and digestive tract scarring and prolonging survival in the dystrophic epidermolysis bullosa model mice. Also in the skin ulcer model, administration of the specific HMGB1 fragment peptide was found to inhibit the fibrosing of skin during the healing process of the ulcer. Based on these findings, the present application provides pharmaceutical compositions for the treatment of fibrotic diseases, which comprise the specific HMGB1 fragment peptide.

Abstract: (Objective) An objective of the present invention is to provide therapeutic agents that, in association with stimulation of PDGFR?-positive cells such as bone marrow mesenchymal stem cells, promote their mobilization into blood and accumulation in a damaged tissue, and induce tissue regeneration in a living body. (Means for solution) Multiple peptides were synthesized, and the migration-promoting activity of each peptide was evaluated. As a result, the present inventors successfully identified multiple peptides that have migration-promoting activity on a PDGFR?-positive bone marrow mesenchymal stem cell line (MSC-1). Further, the present inventors confirmed that the identified peptides also have migration-promoting activity on skin fibroblasts, which are PDGFR?-positive cells.

Abstract: The purpose of the present invention is to provide a novel medicine that is effective in treating cerebral infarction. The present invention provides a pharmaceutical composition that contains a peptidyl-prolyl cis-trans isomerase B (PPIB) protein, a nucleic acid encoding the PPIB protein, or a cell that secretes the PPIB protein.

Abstract: The present inventors have found that HMGB1 fragment peptides having a particular amino acid sequence exhibit the effects of improvement of cardiac function, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of dilated cardiomyopathy, that the particular HMGB1 fragment peptides also exhibit the effects of improvement of cardiac function, inhibition of cardiomegaly, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of ischemic cardiomyopathy caused by old myocardial infarction, and that the particular HMGB1 fragment peptides exhibit the effects of inhibition of cardiomyocyte hypertrophy and inhibition of myocardial fibrosis in an animal model of hypertensive cardiomyopathy.

Abstract: (Objective) An objective of the present invention is to provide therapeutic agents that, in association with stimulation of PDGFR?-positive cells such as bone marrow mesenchymal stem cells, promote their mobilization into blood and accumulation in a damaged tissue, and induce tissue regeneration in a living body. (Means for solution) Multiple peptides were synthesized, and the migration-promoting activity of each peptide was evaluated. As a result, the present inventors successfully identified multiple peptides that have migration-promoting activity on a PDGFR?-positive bone marrow mesenchymal stem cell line (MSC-1). Further, the present inventors confirmed that the identified peptides also have migration-promoting activity on skin fibroblasts, which are PDGFR?-positive cells.

Abstract: (Objective) An objective of the present invention is to provide therapeutic agents that, in association with stimulation of PDGFR?-positive cells such as bone marrow mesenchymal stem cells, promote their mobilization into blood and accumulation in a damaged tissue, and induce tissue regeneration in a living body. (Means for solution) Multiple peptides were synthesized, and the migration-promoting activity of each peptide was evaluated. As a result, the present inventors successfully identified multiple peptides that have migration-promoting activity on a PDGFR?-positive bone marrow mesenchymal stem cell line (MSC-1). Further, the present inventors confirmed that the identified peptides also have migration-promoting activity on skin fibroblasts, which are PDGFR?-positive cells.

Abstract: Biologically low invasive vessels are filled with biological factors that have the activity of mobilizing specific functional cells in the body. The vessels are indwelled in the body. After specific functional cells are mobilized into the vessels, the vessels are removed from the body to collect functional cell populations mobilized to the vessels. Alternatively, the cells are directly collected from the vessels indwelled in the body.

Abstract: (Objective) An objective of the present invention is to provide therapeutic agents that, in association with stimulation of PDGFR?-positive cells such as bone marrow mesenchymal stem cells, promote their mobilization into blood and accumulation in a damaged tissue, and induce tissue regeneration in a living body. (Means for solution) Multiple peptides were synthesized, and the migration-promoting activity of each peptide was evaluated. As a result, the present inventors successfully identified multiple peptides that have migration-promoting activity on a PDGFR?-positive bone marrow mesenchymal stem cell line (MSC-1). Further, the present inventors confirmed that the identified peptides also have migration-promoting activity on skin fibroblasts, which are PDGFR?-positive cells.

Abstract: Biologically low invasive vessels are filled with biological factors that have the activity of mobilizing specific functional cells in the body. The vessels are indwelled in the body. After specific functional cells are mobilized into the vessels, the vessels are removed from the body to collect functional cell populations mobilized to the vessels. Alternatively, the cells are directly collected from the vessels indwelled in the body.

Abstract: Fragment peptides having a proper length, which consists of a portion of the HMGB1 protein were synthesized, and the peptides were confirmed to show therapeutic effects on injury of the spinal cord.

Abstract: A fragment peptide having a proper length composed of a part of an HMGB1 protein was synthesized and the peptide was confirmed to exhibit therapeutic effects on myocardial infarction.

Abstract: A control device for a vehicle includes: a motor generator mechanically connected to an output shaft of an engine; a main battery electrically connected to the motor generator; a sub battery electrically connected to an electric load of the vehicle; and a relay adapted to switch whether the batteries are to be electrically connected or not by turning the relay on or off. The relay is turned off during a powering operation of the motor generator, and the relay is turned on during a regenerative operation of the motor generator. It is determined that the relay is off-fixed in a case where a voltage of the second battery is a predetermined voltage or lower or a charge current of the second battery is a predetermined current or smaller in a state that a command to turn on the relay is outputted during the regenerative operation of the motor generator.

Abstract: A control device for a vehicle includes a relay adapted to switch whether a first battery electrically connected to a motor generator and a second battery electrically connected to an electric load of the vehicle are to be electrically connected or not by turning on/off the relay. The relay is turned off during a power operation of the motor generator to disconnect an electric connection between the first battery and the second battery. The relay is turned on during a regenerative operation of the motor generator to electrically connect the first battery and the second battery. In a case where an on-fixation failure of the relay is detected, the power operation of the motor generator is prohibited.

Abstract: A fragment peptide having a proper length composed of a part of an HMGB1 protein was synthesized and the peptide was confirmed to exhibit therapeutic effects on myocardial infarction.

Abstract: Fragment peptides having a proper length, which consists of a portion of the HMGB1 protein were synthesized, and the peptides were confirmed to show therapeutic effects on injury of the spinal cord.

Abstract: A control device for a vehicle includes a relay adapted to switch whether a first battery electrically connected to a motor generator and a second battery electrically connected to an electric load of the vehicle are to be electrically connected or not by turning on/off the relay. The relay is turned off during a power operation of the motor generator to disconnect an electric connection between the first battery and the second battery. The relay is turned on during a regenerative operation of the motor generator to electrically connect the first battery and the second battery. In a case where an on-fixation failure of the relay is detected, the power operation of the motor generator is prohibited.

Abstract: A control device for a vehicle includes: a motor generator mechanically connected to an output shaft of an engine; a main battery electrically connected to the motor generator; a sub battery electrically connected to an electric load of the vehicle; and a relay adapted to switch whether the batteries are to be electrically connected or not by turning the relay on or off. The relay is turned off during a powering operation of the motor generator, and the relay is turned on during a regenerative operation of the motor generator. It is determined that the relay is off-fixed in a case where a voltage of the second battery is a predetermined voltage or lower or a charge current of the second battery is a predetermined current or smaller in a state that a command to turn on the relay is outputted during the regenerative operation of the motor generator.

Abstract: (Objective) An objective of the present invention is to provide therapeutic agents that, in association with stimulation of PDGFR?-positive cells such as bone marrow mesenchymal stem cells, promote their mobilization into blood and accumulation in a damaged tissue, and induce tissue regeneration in a living body. (Means for solution) Multiple peptides were synthesized, and the migration-promoting activity of each peptide was evaluated. As a result, the present inventors successfully identified multiple peptides that have migration-promoting activity on a PDGFR?-positive bone marrow mesenchymal stem cell line (MSC-1). Further, the present inventors confirmed that the identified peptides also have migration-promoting activity on skin fibroblasts, which are PDGFR?-positive cells.

Abstract: The present invention for the first time demonstrated that: (1) bone marrow-derived pluripotent tissue stem cells can be induced in peripheral blood by intravenously administering tissue extract prepared from isolated skin pieces; (2) the substance in the isolated skin pieces, which is responsible for mobilizing bone marrow-derived pluripotent tissue stem cells to peripheral blood, is HMGB1; and (3) HMGB1 with the activity of mobilizing bone marrow-derived pluripotent stem cells to peripheral blood can be easily purified from cultured cells.

Abstract: It was revealed that the intravenous administration of HMGB-1 and S100A8 promoted the healing of skin ulcer by recruiting bone marrow-derived cells to the site of skin ulcer. Furthermore, when HMGB-1 was intravenously administered to cerebral infarction model mice after creation of cerebral infarction, bone marrow-derived cells expressing nerve cell markers were detected in their brain. A marked cerebral infarct-reducing effect was observed in mice intravenously administered with HMGB-1 as compared to the control. The post-cerebral infarction survival rate was increased in the intravenous HMGB-1 administration group. The involvement of bone marrow pluripotent stem cells in the process of bone fracture healing was assessed using mice, and the result demonstrated that bone marrow-derived cells distant from the damaged site migrated to the bone fracture site to repair the damaged tissue.